Bruce Graham, MD
Cardiovascular Disease · Muncie, INNPI 1598734659
Payments from drug & device makers
What this record shows
22 manufacturers reported payments, led by Boston Scientific at 33.1% of the total.
Across 132 payments — averaging $38.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$2K
- Medtronic$1K
- Abbott$543
- Johnson & Johnson$347
- Pfizer$187
- Novartis$177
- plus $747 from 16 others
Across 143 payments — averaging $2914.14 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$116K
- Astrazeneca UK Limited$86K
- Livanova USA, Inc.$84K
- AstraZeneca$43K
- Boston Scientific$35K
- Janssen Research & Development, LLC$25K
- plus $28K from 3 others
What the payments were for
- Travel & lodging$2,33347%
- Food & beverage$2,68453%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 10 | $1,662 |
| Medtronic | 14 | $1,353 |
| Abbott | 50 | $543 |
| Johnson & Johnson | 3 | $347 |
| Pfizer | 13 | $187 |
| Novartis | 7 | $177 |
| Shockwave Medical, Inc | 7 | $167 |
| Philips North America LLC | 5 | $95 |
| Edwards Lifesciences | 3 | $74 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $53 |
| Abiomed | 1 | $43 |
| Cardiva Medical, Inc. | 2 | $42 |
| AstraZeneca | 1 | $37 |
| Cardiovascular Systems Inc. | 2 | $36 |
| Elutia, Inc. | 2 | $34 |
| Lexicon Pharmaceuticals, Inc. | 2 | $32 |
| Esperion Therapeutics, Inc. | 2 | $30 |
| Terumo Medical Corporation | 1 | $30 |
| E.r. Squibb & Sons, L.L.C. | 1 | $22 |
| Inspire Medical Systems, Inc. | 1 | $20 |
| Cordis US CORP. | 1 | $17 |
| Cvrx, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- WATCHMAN Access System$1,453
- Micra$1,055
- Tremfya$347
How this compares
$5,016 in reported general payments places this provider in the 65th percentile of 408 cardiovascular disease providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 311 | $406,604 |
| XareltoRivaroxaban | 114 | $135,199 |
| BrilintaTicagrelor | 158 | $131,987 |
| EntrestoSacubitril/Valsartan | 75 | $104,010 |
| Repatha SureclickEvolocumab | 61 | $59,555 |
| JardianceEmpagliflozin | 38 | $31,358 |
| MultaqDronedarone Hcl | 22 | $25,355 |
| Praluent PenAlirocumab | 12 | $10,132 |
| Ranolazine ErRanolazine | 72 | $9,648 |
| Ezetimibe | 279 | $7,655 |
| Atorvastatin Calcium | 584 | $6,726 |
| ClopidogrelClopidogrel Bisulfate | 544 | $6,550 |
| Metoprolol Succinate | 446 | $5,472 |
| Amiodarone Hcl | 143 | $2,836 |
| Prasugrel Hcl | 25 | $2,485 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $187 | $406,604311 claims |
| Johnson & JohnsonXarelto | $347 | $135,199114 claims |
| AstraZenecaBrilinta | $37 | $131,987158 claims |
| NovartisEntresto | $177 | $104,01075 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 408 cardiovascular disease providers in Indiana.
Other cardiovascular disease in Muncie
- Mansour AlmnajamMuncie$69K
- Antonio Navarrete-CasasMuncie$39K
- John MillerIndianapolis$354K
- David KovacichIndianapolis$327K
- Wai LeeElkhart$321K
- Anas SafadiHobart$295K
- Lawrence RinkBloomington$280K
- Vijay RaoIndianapolis$247K
- Steven SteinhublLafayette$247K
- Atul ChughIndianapolis$242K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.